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Self-renewal and phenotypic 
conversion are the main 
physiological responses of 
macrophages to the endogenous 
estrogen surge
Giovanna Pepe1, Daniele Braga2,3, Tiziana A. Renzi4,5,†, Alessandro Villa1, Chiara Bolego6, 
Francesca D’Avila2,3, Cristina Barlassina2,3, Adriana Maggi1, Massimo Locati4,5 & 
Elisabetta Vegeto1
Beyond the physiology of reproduction, estrogen controls the homeostasis of several tissues. Although 
macrophages play a key role in tissue remodeling, the interplay with estrogen is still ill defined. Using 
a transcriptomic approach we first obtained a comprehensive list of genes that are differentially 
expressed in peritoneal macrophages in response to physiological levels of 17β-estradiol (E2) injected 
in intact female mice. Our data also showed the dynamic nature of the macrophage response to E2 
and pointed to specific biological programs induced by the hormone, with cell proliferation, immune 
response and wound healing being the most prominent functional categories. Indeed, the exogenous 
administration of E2 and, more importantly, the endogenous hormonal surge proved to support 
macrophage proliferation in vivo, as shown by cell cycle gene expression, BrdU incorporation and cell 
number. Furthermore, E2 promoted an anti-inflammatory and pro-resolving macrophage phenotype, 
which converged on the induction of genes related to macrophage alternative activation and on 
IL-10 expression in vivo. Hormone action was maintained in an experimental model of peritoneal 
inflammation based on zymosan injection. These findings highlight a direct effect of estrogen on 
macrophage expansion and phenotypic adaptation in homeostatic conditions and suggest a role for this 
interplay in inflammatory pathologies.
Macrophages are key cells in inflammation and immunity and can adopt different activation states depending 
on the activating signal and context. Schematically, inflammatory macrophages adopt a classical (M1) activation 
phenotype, which is mimicked in vitro by exposure to interferon-γ and toll-like receptor ligands, characterized by 
the synthesis and/or secretion of cytotoxic and chemotactic mediators that promote inflammation and the killing 
of pathogens and tumors. Immunoregulatory signals produced by surrounding cells, including interleukin-4 
(IL-4) and IL-13, or by activated macrophages, namely IL-10 and TGFβ , stimulate alternative programs of pheno-
typic activation which promote resolution of inflammation, tissue repair, and homeostasis restoration, frequently 
alluded to as M2. M1 and M2 activation states are two extremes of a range of intermediate phenotypes that mac-
rophages can acquire through their unique ability to integrate a vast array of signals under the constraint of envi-
ronmental factors. The macrophage phenotype is also influenced by systemic endogenous molecules that tune 
their ability to respond to danger signals, as exemplified by glucocorticoid hormones1. Thus, different activation 
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profiles provide reactive macrophages with immune and metabolic properties that address them towards special-
ized tasks sustained by distinct gene expression programs2.
Estrogen hormones are lipophilic molecules with pleiotropic functions including a well-documented influ-
ence on the inflammatory process, as revealed by the variation of chronic inflammatory diseases occurrence 
and response to infections in relation with the menstrual cycle, pregnancy and menopause3,4. Estrogen effects 
on immune activity are also revealed by the higher rate of autoimmune diseases in women when compared to 
men, and by the strict dependence of symptomatology depending on women’s estrogen levels5. Experimental 
models have shown that the development of innate immune cells and the immune responses to danger sig-
nals are highly influenced by estrogen, converging on an anti-inflammatory effect of this hormone in dose and 
context-dependent manners4,6. Accordingly, animal models of inflammation are highly responsive to estrogen 
insufficiency and replacement.
Estrogen action is mediated by its interaction with estrogen receptors (ERs), ERα and ERβ , which operates as 
hormone-regulated transcription factors as well as through non-genomic effects, such as calcium influx or lipid 
kinase activation, also mediated by a more recently described G protein-coupled estrogen receptor, GPR30. ERs 
and GPR30 were shown to be expressed by human and mouse macrophages and to influence inflammation, with 
ERα being one key mediator of the estrogen anti-inflammatory activity in these cells6–10. While the impact of 
estrogen and macrophage physiology is gaining intriguing insights for both endocrine and immune implications 
and for human pathologies11,12, our knowledge of the transcriptional response of macrophages to this hormone is 
limited to the effect of the hormone on specific molecular targets, such as VEGFα or inflammatory cytokines, in 
cells exposed to specific immunologic ligands13–15. The aim of this study was to provide a comprehensive descrip-
tion of the transcriptional response of macrophages to this hormone evaluating the genomic and functional 
response of macrophages exposed in vivo to physiological changes in estrogen levels.
Results
Gene expression profiling of peritoneal macrophages in response to estrogen in vivo. ERs 
are ligand-dependent transcription factors that induce genomic responses by the direct interaction with target 
gene promoters as well as through indirect secondary mechanisms. Since peritoneal macrophages were shown 
to express ERs13,15, we envisioned to analyze the transcriptomic response to estrogen of peritoneal macrophages. 
Female mice were selected in the metaestrous (ME) phase of the estrous cycle, bearing low levels of circulating 
estrogens, and either left untreated or injected with a physiological dose of E2. This approach provides an exper-
imental asset to more faithfully mimic the mechanisms induced by the physiological estrogen surge in intact 
animals. After 3 or 24 h of hormone injection, peritoneal macrophages were purified by immunosorting, RNA 
extracted and analyzed by RNA sequencing. Our data show that short and long term hormonal treatments signif-
icantly affected expression levels of 569 transcripts in total. When data were analyzed grouping up- or down-reg-
ulated differentially expressed genes (DEGs) according to onset and duration of hormone action considered as 
net effect, four gene clusters could be identified: cluster I) collects DEGs related to early and transient effects 
(only regulated at 3 h); cluster II) gathers DEGs supporting persistent responses (similarly modulated by 3 and 
24 h treatments); cluster III) includes early and progressively responsive genes (regulated at 3 h and furthermore 
at 24 h treatment); cluster IV) contains late responsive genes (only influenced after 24 h treatment) (Fig. 1a). 
Analysis of clusters kinetics showed that a significant fraction of DEGs (35%; clusters I + II) are already modu-
lated 3 h after E2 administration thus behaving as early responsive genes. Only a minor fraction of them returned 
to control levels after 24 h treatment (16%; cluster I), while the majority of all DEGs are modulated at this late 
time point (84%; clusters II + III + IV). Progressively responsive genes represent the highest number of regulated 
genes (37%; Cluster III), while genes regulated only at late time point constitute a high proportion of genes (28%; 
cluster IV) (Fig. 1b). The list of differentially expressed genes (DEGs), ranked by their sensitivity to estrogen in 
comparative analyses, and its association with the respective cluster is shown in Supplementary Table 1.
Several transcription factors, including ERs, may participate in regulating DEGs expression. In order to gain 
insight into the mechanisms of hormone responsiveness, motif enrichment analysis was conducted to search for 
transcriptional regulatory elements in the promoters of macrophage DEGs. Each cluster included unique tran-
scription factors that are involved either in the up- or down-regulation effects, with up-regulated genes in cluster 
I showing a high abundance of binding sites for C/EBP transcription factors, an enrichment for E2f binding sites 
in cluster II, and for Irf and Stat families of transcription factors in cluster IV (Fig. 1c). In parallel, specific tran-
scriptional regulators are involved also in the down-regulation of DEGs in a cluster-specific manner. Analysis of 
ER binding sites16 shows cross-interference among different clusters, as this regulatory element is enriched with 
similar frequency of DEGs enhancers/promoters in all fours clusters (Fig. 1c and Supplementary Table 1). Thus, 
these analyses support the hypothesis that early and late effects induced by estrogen on macrophage transcrip-
tome are mediated by direct ERE-mediated mechanisms as well as by the ordered engagement of distinct sets of 
transcription factors that allow the specific temporal profile of gene regulation observed in response to estrogen. 
Taken together, these data show that the in vivo administration of a physiological dose of E2 results in the reg-
ulation of expression of a distinct set of genes in macrophages, an effect which is evident shortly after hormone 
administration and progresses with time through a balanced combination of positive and negative distinct or 
overlapping pathways.
Functional modifications associated with estrogen action in macrophages. In order to trans-
late comprehensive genomic information into functional relevance, we performed functional annotation anal-
yses using Gene Ontology term enrichment to search for significant terms related with biological programs. 
Enrichment of specific biologic categories (Supplementary Table 2) showed that, in analogy with gene expres-
sion, the time-course evaluation of estrogen action identifies biological programs that are either uniquely or 
commonly regulated as early or late responses to estrogen in macrophages (Fig. 2a). Genes showing early and 
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transient response to estrogen resulted enriched in specific gene ontologies including transcription factors, apop-
tosis, stress response, and protein folding, while the ontology related with lipid metabolism was enriched as a 
late responsive pathway. However, three functional programs clearly emerged as persistent estrogen-responsive 
pathways in macrophages: these relate with cell cycle, immune response, and wound healing. As shown in Fig. 2b, 
a search for functional interactions using the String database resulted in a high number of connections among 
proteins encoded by genes involved in the Cell cycle, Immune response and Wound healing processes. The first 
category appears to be supported by the coordinated regulation of a core of highly interconnected genes, while 
the last two categories share a high number of proteins modulated by estrogen and are known to converge on the 
alternative polarization of macrophages (Fig. 2b). Interestingly, some of the transcription factors shown in Fig. 1c 
are known to be involved in cell cycle progression, including C/EBPs and E2fs or in the control of inflammation 
and macrophage polarization, including NF-kB, FOXP1 and Gabpa17, while some others were shown to regulate 
both processes, such as Myc18, further supporting the functional implications of estrogen action on macrophages 
and providing a first hint on the underlying molecular mechanisms. Altogether, these results show that estrogen 
Figure 1. The transcriptome analysis of peritoneal macrophages in response to estrogen. Non-elicited 
peritoneal macrophages obtained from metaestrous (ME) female mice were analyzed by RNA sequencing 
after the in vivo treatment with vehicle (time 0, n = 3) or E2 administration for 3 (n = 3) or 24 h (n = 3). (a) The 
temporal expression profile of DEGs is represented as heat map (red, high relative expression; black, mean 
expression; green, low relative expression). (b) By k-means clustering calculations, DEGs were grouped in 
4 clusters according to the absolute variation in their expression profile. The number of up (red) and down 
(green)-regulated genes in each cluster is shown. Gene expression levels are shown in relation to the mean 
expression value of the DEGs in each cluster (magenta line). (c) Transcription factors (Txf) that bind putative 
binding sites in up (+ ) or down (− )-regulated genes are listed for each cluster; the column on the right shows 
the number of genes with Txf binding sites in their promoters reported as the percentage of the total number of 
up (+ ) or down (− )-regulated genes in each cluster. Esr1/2: binding sites for estrogen receptors16.
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induces in macrophages specific biological pathways related to distinct functional responses supported by an 
highly interconnected network of hormone-responsive genes.
Estrogen modulates gene expression in isolated macrophages. Binding sites for ERs are present 
in the promoters of some of the DEGs in clusters I-IV. In order to ascertain that the transcriptional response of 
macrophages to estrogen was mediated by a direct effect of the hormone, macrophages were grown in culture and 
assayed for estrogen action on the expression of target genes, with or without EREs in their promoters. Peritoneal 
macrophages and BMDMs were cultured ex vivo and assayed for the expression of estrogen target genes in 
response to E2; since the peritoneal fluid in women may contain micromolar concentrations of ovarian hormones 
through exudation during ovarian follicle development and rupture, E2 concentrations higher than the nanomolar 
plasmatic range were also tested, although anatomical differences may lead to a reduction in estrogen concentra-
tions in the female mouse peritoneum19,20. As shown in Fig. 3a, transcripts coding for Angtpl-4 and VEGFα , clus-
ter I and II ERE-positive genes respectively, were modulated by increasing concentrations of estrogen in isolated 
macrophages. Interestingly, levels of transcript coding for Arg1, a cluster II gene with no ERE in its promoter/
enhancer region, were also significantly increased by short-term estrogen treatment, though the overall effect 
of estrogen was significantly lower. The effect of hormone in isolated macrophages was similar to that observed 
in vivo with superimposable fold-inductions in the mRNAs analyzed (see Fig. 3 and Supplementary Table 1). To 
further validate the involvement of estrogen-specific signaling pathways, we evaluated hormone action on the 
Figure 2. Biological pathways regulated by E2 in macrophages. (a) The DEGs list from RNA sequencing 
analysis was submitted to the DAVID database for functional annotation. GO ontologies significantly 
modulated following 3 or 24 h of estrogen treatment are represented, with the number of genes regulated 
in each ontology reported as % of all regulated genes at each treatment. Immune response includes Immune 
response, Chemotaxis and Endocytosis; Wound healing includes Response to wounding, Hemopoietic/
lymphoid organ development and Blood vessel development; Lipid metabolism includes Positive regulation of 
lipid metabolic process, Cholesterol metabolic process and Lipid localization. Ontology gene lists are reported 
in Supplementary Table 2. (b) String diagram of the interactions among regulated genes. Genes of the Cell cycle 
(blue), Immune response (green) and Wound healing (red) are evidenced, with commonly regulated genes 
resulting in purple (Cell cycle + Immune response) and yellow (Immune response + Wound healing). The Venn 
diagram in the insert shows the numbers of unique or common regulated genes. (See Supplementary Figure 3 
for a high resolution image of panel b).
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genes reported above using macrophages from ERα -KO animals. Consistent with previous reports from this and 
other groups6,8,21,22 ablation of ERα gene resulted in loss of estrogen action in macrophages, as estrogen-induced 
changes in the mRNA levels coding for Vegfα , Angtpl4 and Arg1 observed in WT cells were not detected in 
ERα -KO macrophages (Fig. 3b). Altogether, these data suggest that estrogen acts directly on macrophages to 
induce a complex gene expression program mediated, at least in part, by the ERα receptor.
Estrogen regulates the expression of genes associated to proliferation and macrophage polar-
ization. The identification of estrogen-responsive genes and the indication of specific biological pathways 
modified by estrogen suggest that macrophages may undergo functional changes in response to varying hor-
monal levels. Cell replication and polarization consistently emerged as hormone-responsive programs and were 
thus selected for deeper investigation. We thus set our next experiments to extend our observation by further 
modifying hormonal treatments and, more importantly, to evaluate the effects of changes in endogenous estro-
gen. As a first step, gene expression data obtained by RNA sequencing were validated using semi-quantitative 
analyses on peritoneal macrophages extracted from female mice at ME or following E2 treatments for 3, 24 and 
48 h. In addition, a group of females in the estrous phase, which immediately follows the rapid physiological surge 
of estrogens, were also included in the analyses in order to evaluate macrophage gene expression in response 
to the endogenous increase in female hormones. Figure 4a and b show that mRNA levels of genes associated to 
actively replicating cells, such as Ki67 and Ube2c, and coding for proteins related with cell cycle phases, namely 
CcnD1 gene for the G1/S phase and CcnB2 and Cdk1 genes for the G2/M phase, were increased following the 
administration of exogenous estrogen. For all genes but Ki67 and CcnD1, the highest induction was reached after 
3 h treatment followed by a substantial decrease at later time-points. Interestingly, the expression of some of these 
genes was also significantly increased in the estrous phase, showing that also the endogenous surge of female hor-
mones is followed by an increased expression of cell cycle and replication genes in macrophages. Transcripts cod-
ing for proteins associated with macrophage polarization phenotypes, such as Arg1, Ym1, CD206 and VEGFα , 
were also upregulated by estrogen with the highest induction occurring shortly after hormone administration. 
Interestingly, for these genes the effect was still observed at extended time points (Fig. 4c). Arg1 and Vegfα 
mRNAs are also increased in macrophages from females at estrous, further demonstrating that the endogenous 
surge of female hormones is associated with an increased expression of genes that are related with the immune 
polarization of these cells. Taken together, these data demonstrate that genes coding for proteins involved in cell 
cycle progression and in M2 polarization are induced by an increase in either exogenous or endogenous estrogen 
levels.
Figure 3. Regulation of target gene expression by E2 in isolated macrophages. Peritoneal macrophages 
(perMP) and BMDM were grown in culture and assayed for gene expression following E2 administration. (a) 
Macrophage cells were treated with vehicle (veh, open bars) or increasing concentrations of E2 (10–9, 10−7 and 
10−5 M, filled bars) for 3 h. Real time PCR was used to analyze the mRNA levels coding for Vegfα , Angtpl4 and 
Arg1. (b) Comparison of estrogen action in BMDM cells from WT and ERα -KO (ERKO) mice. The mRNA 
levels coding for Vegfα , Angtpl4 and Arg1 were analyzed 24 h after the addition of vehicle (veh, open bars) or 
10−7 M E2 (filled bars). Data sets for each gene were calculated using the 2−ddCt method with respect to the mean 
value of the vehicle group. Bars represent mean values ± SEM (n = 4). *p < 0.05; **p < 0.01 versus veh.
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Increased estrogen levels promote macrophage proliferation in vivo. Peritoneal macrophages are 
maintained in steady state by a low rate self-renewal process23–25. As transcriptional profile data show that estro-
gen regulates a significant number of genes associated to proliferation while having a minor effect on inflam-
matory cytokines involved in leukocyte recruitment, we addressed the possibility that E2 acts as a proliferative 
signal for peritoneal macrophages. In agreement with its induction at the transcriptional level (Fig. 4a and b), a 
significant increase in the fraction of Ki67+ peritoneal macrophages was observed in animals treated for 24–48 h 
with E2 (Fig. 5a and b). Accordingly, females in the estrous phase have a higher number of Ki67+ macrophages 
cells in the peritoneum compared with ME females (Fig. 5b). Thus, these results suggest that an increase in circu-
lating estrogen levels enhances the proliferation rate of peritoneal macrophages. To further extend this functional 
evidence, BrdU was administered in vivo 2 h before sacrifice and its incorporation into the DNA of peritoneal 
macrophages was assessed to quantify cells in the S-phase of the cell cycle. Figure 5c shows that a 24 h treatment 
Figure 4. Validation of E2 target genes in peritoneal macrophages in vivo. Peritoneal macrophages were 
isolated from female mice at the metaestrous phase (ME) of the estrous cycle or treated with E2 for 3, 24 and 
48 h. Females in the estrous phase (E) were also investigated. Real time PCR was performed to detect the 
mRNAs coding for genes related with cell cycle phases (a) G1/S (CcnD1, E2f1), (b) G2/M (CcnB2, Cdk1, 
Ube2c; Ki67) and (c) alternative polarization (Arg1, Ym1, CD206, Vegfα ). Data sets for each gene were 
calculated using the 2−ddCt method with respect to the mean value of the control group (ME). Bars represent 
mean values ± SEM (n = 5–10). *p < 0.05; **p < 0.01; ***p < 0.001 versus ME.
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with E2 significantly increased the percentage of cells that were duplicating their DNA. BrdU incorporation was 
not increased in the other experimental groups, suggesting that the effect on DNA duplication was restricted 
to a specific time window of E2 action encompassing the first 24 h after treatment without being detected in 
the estrous phase or at a later time point (48 h; Fig. 5d), when the increased number of cells progressing in the 
cell cycle (assessed by Ki67 expression in Fig. 5b) is probably too small to allow the detection of cells within the 
S-phase. Of note, the amplitude of estrogen action on BrdU incorporation is similar to that reported for IL-4, 
the best-characterized signal inducing local expansion of peritoneal macrophages in inflammatory conditions26.
As genomic data and functional evidence indicated that an increased number of macrophages in the S-phase 
of the cell cycle is present in the peritoneum of estrogen-treated female mice, we asked whether the number of 
peritoneal macrophages could be influenced by alterations in the endogenous levels of estrogen. Indeed, ova-
riectomized (ovx) female mice, in which production and biological effects of endogenous estrogen are ceased, 
showed a significant reduction in the number of peritoneal macrophages as compared to sham-operated animals, 
an effect that was completely reverted by a long-term exposure to exogenous E2 (Fig. 5e). Peritoneal macrophages 
are a heterogeneous population of cells, which includes large peritoneal macrophages (LPM), characterized by 
the expression of the transcription factor Gata6, and small peritoneal macrophages (SPM), a less abundant subset 
of macrophages that derive from circulating monocytes23–25. The abundance of LPS, SPM and other leukocyte 
populations, as well as the efficiency of cell recovery procedures were not altered by changes in estrogen levels (see 
Supplementary Fig. 2). Altogether, these data demonstrate that the endogenous or exogenous surge of estrogen 
enhances peritoneal macrophage proliferation. The proliferative signature of macrophages exposed to estrogen 
correlates with an increase in their number, in the absence of a significant increase in other leukocyte types.
Estrogen promotes macrophage alternative polarization in an in vivo model of self-resolving 
inflammation. Among estrogen-regulated gene ontologies, the Immune response and Wound healing cat-
egories include overlapping functions associated with the alternative polarization of macrophages, a process 
that progressively shapes macrophage immunometabolic properties to sustain the resolution of inflamma-
tion and tissue remodeling. To evaluate macrophage polarization as a dynamic response to estrogen, ovariec-
tomized mice were repeatedly administered estrogen for prolonged periods of time and macrophages were 
sorted from the peritoneum and analyzed for their expression of genes associated with the polarized activation. 
Ovariectomy did not alter the basal expression of Arg1, Tgm2, and Vegfα mRNAs, while E2 treatment signifi-
cantly increased the mRNA levels of these M2 markers (Fig. 6a), consistent with our results reported in Fig. 4 
and Supplementary Table 1. Of note, also in this setting we detected a significant induction of Ki67 expression, 
in agreement with the proliferative effect observed on peritoneal macrophages (Fig. 5). Interestingly, polariza-
tion gene expression returned to basal levels after 60 h of estrogen replacement, suggesting that this late time 
point was either associated with a reduced responsiveness to estrogen or that a phenotypic transition of mac-
rophages to the resolution phase was occurring27. Consistent with this latter hypothesis, after long time expo-
sure to estrogen macrophages showed a significant increase in IL-10 expression (Fig. 6a), a key mediator in the 
resolution phase of inflammation27, together with a reduction in F4/80 mean fluorescence intensity (see Fig. 5e 
and Supplementary Fig. 2). These results demonstrate that, beyond proliferation, estrogen induces polarization 
phenotype in peritoneal macrophages that progressively evolves with time through specialized anti-inflammatory 
and reparative immune properties.
To define the functional relevance of these events, we adopted a mouse model of transient self-resolving peri-
toneal inflammation induced by zymosan injection, in which the initial phase of inflammation associated with a 
massive recruitment of PMN and a concomitant reduction in the number of peritoneal macrophages is followed 
by the spontaneous resolution of the inflammatory process accompanied by a modest recruitment of monocyte 
and the progressive return to normal values of peritoneal macrophages28,29. The role of estrogen in the model 
was evaluated treating ovx mice with vehicle or E2 immediately before zymosan injection and after 24 and 48 h 
and monitoring its impact on the kinetics of infiltrating cells during the course of inflammation. Sham-operated 
female mice were used as controls. In agreement with results shown in Fig. 5f, neither ovx nor estrogen admin-
istration to ovx mice influenced the number of PMN or monocytes, which varies in the peritoneum during the 
course of the inflammatory reaction (Fig. 6b and c, respectively). The absence of estrogen did not influence the 
cellular repopulation of the peritoneum, at least within the time frame analyzed in this experiment, but a signif-
icant increase in number of peritoneal macrophages was observed after long term estrogen treatment (Fig. 6d), 
indicating that estrogen administration provides an immune trigger for macrophages, in agreement with data 
reported in Fig. 5. Of note, also in these experimental settings estrogen induced the expression of polarization 
genes in macrophages. Zymosan-induced expression of Arg1 was potentiated by 36 h estrogen treatment in ovx 
animals, and its reduced expression after 60 h zymosan injection in ovx compared to sham-operated animals is 
partially rescued by estrogen administration (Fig. 6e). Similarly, the induction of Vegfα mRNA was also modu-
lated by hormone levels after 36 h of inflammation (Fig. 6f). In agreement with this anti-inflammatory effect of 
estrogen, TNFα expression is increased by hormone loss and strongly reduced by estrogen treatment (Fig. 6g), 
and IL-10 mRNA levels are significantly higher in animals treated for 60 h with estrogen as compared to sham 
or ovx animals. Thus, during local inflammation estrogen effects progress with time to support an increase in 
number of peritoneal macrophages and their alternative polarization to sustain the resolution phase. Altogether, 
these data demonstrate that estrogen increases macrophage number and dynamically shapes their phenotype to 
promote their anti-inflammatory and healing properties.
Discussion
A combination of mechanisms have been shown to support the effects of estrogen on the immune system, 
including direct genomic and epigenetic effects as well as interactions with transcription factors, co-regulators, 
www.nature.com/scientificreports/
8Scientific RepoRts | 7:44270 | DOI: 10.1038/srep44270
Figure 5. Estrogen induces macrophage proliferation. (a–d), Proliferation was analyzed by evaluating Ki67 
expression and BrdU incorporation by peritoneal macrophages from female mice at ME or 24 and 48 h after 
E2 treatment. Females in the estrus phase (e) were also analyzed. Mice were injected i.p. with BrdU 2 h prior to 
analysis. Representative dot plots depicting gating schemes for Ki67 and BrdU analysis are shown in panels a 
and c, respectively. Doublets were removed based on FL2 scatter width (FL2-W)/FL2 scatter area (FL2-A). Bar 
charts show the percentage of Ki67 (b) and BrdU (d) positive macrophages. Data are representative of three 
independent experiments. Graphs represent the mean ± SEM of 4–9 mice per group. (e), Ovariectomized 
female mice were treated with vehicle (ovx, black bars) or E2 (grey bars) for 60 h. Sham-operated mice treated 
with vehicle were used as controls (open bars). The peritoneal lavage fluid was analyzed by flow cytometry 
to evaluate the percentage of macrophages and other immune cells, as indicated. Results are expressed as the 
mean ± SEM (n = 3). *p < 0.05 versus sham; °p < 0.05 versus ovx.
www.nature.com/scientificreports/
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cytoplasmic signaling pathways and intercellular communications4,30,31. The present integrated analysis of the 
in vivo response of macrophages to estrogen has revealed the existence of a physiological endocrine-immune 
crosstalk that links estrogen action with proliferation of peritoneal macrophages and their immunophenotypic 
adaptation, thus contributing relevant insights to our understanding of estrogen impacts on the regulation of the 
inflammatory response. The experimental conditions and transcriptomic approach adopted have led to a detailed 
temporal prospective of this endocrine-immune interplay and have identified a comprehensive list of molecular 
mediators involved. Clustering analyses according to the onset and duration of estrogen responsiveness clearly 
showed the progressive response of macrophages to the estrogen signal, as some genes were regulated as either 
early or late responses to hormone administration, while others resulted in a sustained or potentiated regulation. 
The biological pathways most prominently modulated included macrophage proliferation, immune response, 
transcription factor expression, amino acid utilization, and energy metabolism, and on a whole indicated a key 
role for estrogen as a physiologic immunoregulatory factor for macrophage biology. Though the identification 
of the molecular mechanisms underlining the genomic events here reported require future investigation, our 
Figure 6. Estrogen induces peritoneal macrophage polarization. (a) Peritoneal lavage fluid was collected 
from sham-operated (not shown), ovariectomized (ovx, shown as time 0) or ovx mice treated with E2 for 36 
or 60 h. Macrophages were immunosorted and analyzed by real time PCR for gene expression. Data show the 
expression levels of genes related with proliferation (Ki67, open circles), alternative activation (Arg1, filled 
squares; Tgm2, open squares) and wound healing (Vegfα , triangles; IL-10, filled circles). Values were calculated 
using the 2−ddCt method and normalized for the value of the sham group used as reference (= 1) for each gene. 
(b–h) Sham-operated (triangles), ovariectomized (open circles), or ovariectomized and treated with E2 (filled 
circles) animals were injected with zymosan and the number of peritoneal macrophages, polymorphonuclear 
cells (PMN) and monocytes was analyzed by flow cytometry at different time points (panels b-d, respectively). 
Immunosorted macrophages were analyzed by real time PCR for the expression of genes, as indicated (panels 
e–h). Values of the sham group were used as reference (= 1) and are not shown; ovx values are shown at time 
0. Data were calculated using the 2−ddCt method and normalized for the value of the sham group for each gene. 
Results are expressed as the mean ± SEM (n = 3). *p < 0.05 versus ovx.
www.nature.com/scientificreports/
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study reveals the identity and temporal responsiveness of a comprehensive set of novel estrogen-responsive genes 
(Supplementary Tables 1 and 2) that represent useful biological indicators of hormone signaling in macrophages.
It has recently been demonstrated that peritoneal macrophages are maintained by local self-renewal, with a 
low level of proliferation throughout life regulated by growth factors and immune mediators including CSF-1 and 
IL-423,32–35. Functional annotation of DEGs suggested that estrogen also acts as a proliferative signal for peritoneal 
macrophages. From a physiological point of view, our results provide a novel view of estrogen action in peritoneal 
homeostasis, in which macrophages are stimulated by estrogen to adapt and develop specific immune regulatory 
functions, possibly to cope with estrogen-induced changes in the environment. The nature of these concomitant 
events may include ovulation, with the need of increased macrophage number and activation in order to handle 
the wound healing response associated with follicle rupture and the induction of an immunotolerant environ-
ment which either favors egg fertilization and further implantation or participates in elimination of dead cells and 
tissue debris resulting from luteal or atretic follicle degradation. The advantage for estrogen to induce macrophage 
proliferation instead of monocytes recruitment is unclear. As the estrogen surge occurs every 4–5 days in mice 
and it is perpetuated throughout the fertile life of females, it is possible that such circumstances direct the request 
of resident macrophages towards the expansion of local cells, a process that is energetically more favorable than 
the constant increase of hematopoietic precursors and their migration into the peritoneum35. This leads to specu-
late that LPM are the cellular target among peritoneal macrophages that respond to the hormonal signal, although 
our data only show a trend in the abundance of this macrophage subset following hormone manipulations, with-
out reaching statistical significance (Supplementary Fig. 2). Further studies are thus needed to better characterize 
the macrophage subset of estrogenic responders. Interestingly, our data also show that genes related with lipid 
metabolism are modulated by the hormone. Although not addressed in the present study, this evidence represents 
an additional indication of the metabolic adaptation of macrophages induced by estrogen which might serve the 
role of directing cholesterol and phospholipid metabolism towards the formation of membranes required for cell 
proliferation.
Macrophage proliferation has been observed in selected murine and human tumors36,37, including peritoneal 
neoplasia38,39 and in Th2 inflammatory conditions26, with variable involvement of IL-4 and CSF-1 depending on 
the specific experimental conditions40. Though a deep investigation of the underlying molecular mechanisms was 
precluded as estrogen proven to be unable to support macrophage proliferation in vitro, similar to what observed 
for IL-4, in our experimental conditions a significant induction of CSF-1 or IL-4 was not observed, arguing 
against the hypothesis that the estrogen effect is mediated by these mediators. Indirect mechanisms involving 
other peritoneal cells able to respond to the hormone cannot be excluded30,41, however we observed that EREs 
are present in the promoter of several cell cycle-related genes identified in the present study, including Chaf1a, 
CcnB2 and Wee116, suggesting a direct binding of estrogen to the promoter of proliferation-related genes in 
macrophages.
This study also provides the first demonstration that in vivo estrogen induces a phenotype resembling alter-
native macrophage activation that further converts towards a pro-resolving phenotype, as shown by changes 
induced by hormone replacement on polarization gene expression culminating with the induction of a key immu-
nosuppressive cytokine typically expressed by macrophages during the resolution phase of inflammation, namely 
IL-10. Importantly, results obtained in the zymosan peritonitis model reveal that these mechanisms are main-
tained during an acute inflammation of the peritoneum. These results are in agreement with previous studies 
which suggested that estrogen is involved in macrophage activation and polarization in experimental models of 
inflammation42–44 or in isolated macrophages/cell lines challenged with specific immune stimuli9,15,45. Our study 
provides a major advancement to this knowledge as it proves estrogen to be per se a physiological regulator of the 
number and reactivity of peritoneal macrophages in intact healthy animals, in the absence of confounding factors 
such as recruited circulating monocytes achieved in wound healing or in different models of peritonitis.
An abundant number of peritoneal macrophages showing a dysregulated polarization have also been 
involved in endometriosis, a pathological condition caused by the ectopic growth of endometrial cells in the 
peritoneum46–48. In particular, estrogen is known to drive detrimental effects on endometrial lesion develop-
ment and progression through its well-recognized activity on endometrial cells49,50. Macrophages are involved in 
growth, sustainment and vascularization of endometriosis lesions, and their ability to switch from inflammatory 
to anti-inflammatory and resolving macrophages is altered in endometriosis46,51–53. In this respect, the present 
description of the estrogen-macrophage signaling has intriguing implications for our understanding of endome-
triosis pathogenesis and therapeutic approaches, and candidate macrophage estrogen-responsive genes identified 
in this study as potential biomarkers in this clinical setting. Furthermore, the expression of the progesterone 
receptor is either absent or very limited in peritoneal macrophages, being below the detection limits in our assay. 
On the contrary, the progesterone receptor is highly expressed in endometrial cells and used as target of current 
therapeutic interventions for endometriosis that use progesterone analogues to block ER activity. The lack of 
progesterone receptor in peritoneal macrophages leaves estrogen action unopposed by progestin drugs in these 
immune cells, with possible reduction in therapeutic efficacy. Although the mechanisms provided in the present 
work suggest detrimental effect on certain pathologies, such as endometriosis, these events might be involved in 
the powerful suppressive influence exerted by estrogen in other inflammatory pathologies, such as those affecting 
the CNS or the lung8,54.
To conclude, these results represent a key advancement for the understanding of the impact of estrogen on 
macrophage physiology and identify novel mechanisms and underlying molecular players of potential patho-
physiological relevance.
Methods
Animal models and treatments. C57BL/6 female mice at 4 months of age were supplied by Charles River 
Laboratories; ERα KO female mice were obtained from P. Chambon, IGBMC, Strasbourg, France55. Animals 
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7:44270 | DOI: 10.1038/srep44270
were allowed to food and water access ad libitum and kept in temperature-controlled facilities on a 12-hour 
light and dark cycle. Animals were housed in the animal care facility of the Department of Pharmacological and 
Biomolecular Sciences at the University of Milan. The phase of the reproductive cycle in female mice was assessed 
by blind analysis of vaginal smears mounted on glass microscope slides and stained with May-Grünwald-Giemsa 
method (MGG Quick Stain Kit; Bio-Optica) according to the manufacturer’s protocol. 17β -estradiol (E2; Sigma-
Aldrich) was administered by a 100 μ L s.c. injection of 5 μ g/kg E2 dissolved in corn oil by o/n stirring in the dark 
at room temperature in order to obtain physiologic plasma levels of E256. Ovariectomy (ovx) or sham surgery was 
performed under mild anesthesia obtained by s.c. injection of 50 μ l solution of ketamine (93.6 mg/kg, Ketavet 100; 
Intervet) and xylazine (7.2 mg/kg, Rompun; Bayer); control animals received corn oil injection. At the specified 
time points, animals were euthanized by intraperitoneal (i.p.) injection of lethal ketamine and xylazine solu-
tion (150 and 12 mg/kg, respectively). Animal groups (n = 3) for the RNA sequencing experiment were given 
an estrogen-free diet (AIN93M; Mucedola) 2 weeks before and throughout the experiment. For the zymosan 
peritonitis model, 4 weeks after sham/ovx surgery mice were injected i.p. with 1 mg of Zymosan (Sigma-Aldrich) 
in 1 ml of 0.9% NaCl, while control mice received physiological solution alone. Animals were sacrificed after 12, 
36 and 60 h. Ovx mice were treated with corn oil or E2 by repeated injections given 3 h before zymosan and 16 h 
before sacrifice at 36 and 60 h. Macroscopic and weight analyses of uterine tissue were used to confirm the success 
of ovx and E2 treatments. For in vivo BrdU labelling experiments, mice were injected i.p. with 30 ul of a 10 mg/
ml solution of BrdU (Sigma-Aldrich) dissolved in 0.9% NaCl. Animals were sacrificed 2 h after BrdU injection 
(n = 4–6). Animal investigation has been conducted in accordance with the ethical standards and according to 
the Declaration of Helsinki and according to the Guide for the Care and Use of Laboratory Animals, as adopted 
and promulgated by the US National Institute of Health, and in accordance with the European Guidelines for 
Animal Care and Use of Experimental Animals. Experiments were approved by the Italian Ministry of Research 
and University and controlled by an internal panel of experts.
Peritoneal and bone-marrow-derived macrophages (BMDMs). Peritoneal cells were recovered by 
peritoneal lavage. Briefly, 5 ml of pre-chilled 0.9% NaCl were injected into the peritoneal cavity using a 21 G 
needle, cell suspension centrifuged and resuspended in PBS + 0.5%BSA. For in vitro assays, peritoneal cells were 
incubated with ACK solution (0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM EDTA; pH 7.3) for 5 minutes at 4 °C and 
seeded at the concentration of 1 × 106 cells/mL in RPMI (Life Technology-Invitrogen) supplemented with 10% 
endotoxin-free FBS, 1% penicillin/streptomycin and 1% Na pyruvate. After 45 minutes and several washes in PBS, 
medium was replaced with RPMI w/o phenol red supplemented with 10% dextran coated charcoal (DCC)-FBS 
(RPMI + 10% DCC). On the next day, cells were treated for 3 h with vehicle or E2 105 M. For RNA sequencing, 
gene expression validations and proliferative index analyses peritoneal cells were isolated by anti-CD11b antibody 
loaded MicroBeads (Miltenyi).; Briefly, 107 peritoneal cells were resuspended in 90 μ L PBS + 0.5% BSA, and 10 μ L 
CD11b MicroBeads were added to the cell suspension and incubated for 15 min at 4 °C. After washing, cells were 
resuspended in 500 uL PBS + 0.5% BSA and applied to LS Miltenyi columns (Miltenyi) for the magnetic sepa-
ration procedure. After 3 washing steps, CD11b-positive cells were eluted from the columns and counted. Cells 
were either stored in TRIzol reagent (Invitrogen) for gene expression studies or fixed for flow cytometry analyses. 
For cell phenotyping and sorting macrophages were analyzed by flow cytometry, as described below.
To prepare BMDMs, bone marrow from the tibia and femur was flushed with RPMI (Life 
Technology-Invitrogen) using a 21 gauge needle. Cells were centrifuged at 1200 rpm for 5 min at 10 °C, 
seeded in flask cell culture T75 in DMEM + GlutaMAX (Life Technology-Invitrogen) supplemented with 
10% endotoxin-free FBS, 1% penicillin/streptomycin and 1% Na pyruvate and incubated o/n. On the next 
day, the supernatant was collected, seeded at the concentration of 5–8 × 106 cells/dish and grown for 6 days in 
DMEM + GlutaMAX containing 20% endotoxin-free FBS, 30% L929-cell conditioned media, 1% penicillin and 
streptomycin, and 1% Na pyruvate. After 6 days BMDMs were harvested with Accutase (Merck-Millipore) and 
plated at the concentration of 5 × 105 cells/ml. On the next day, RPMI medium w/o phenol red with 10% dextran 
coated charcoal-FBS was added and cells were treated for 24 h with vehicle or E2 at the specified concentrations; 
for the 3 h treatment vehicle or E2 were added in the last 3 h of incubation.
RNA preparation and analysis. Total RNA was purified using RNeasy minikit protocol (Qiagen), accord-
ing to the manufacturer’s instructions, including a step with deoxyribonuclease incubation. For real time PCR, 
1 μ g RNA (250 ng in peritonitis model) was used for cDNA preparation using 8 U/μ l of Moloney murine leukemia 
virus reverse transcriptase (Promega) in a final volume of 25 μ l; the reaction was performed at 37 °C for 1 h, 
and the enzyme inactivated at 75 °C for 5 min. Control reactions without the addition of the reverse transcrip-
tion enzyme were performed (data not shown). A 1:4 cDNA dilution was amplified using GoTaq® qPCR Master 
Mix technology (Promega) according to the manufacturer’s protocol. The PCR was carried out in triplicate on a 
96-well plate using 7900HT fast real time PCR system (Applied Biosystems) with the following thermal profile: 
2 min at 95 °C; 40 cycles, 15 sec at 95 °C, 1 min at 60 °C. Primer sequences are reported in Supplementary Table 3. 
Data were analyzed using the 2−ΔΔCt method. For RNA sequencing, RNA Quality Control was performed on all 
RNA samples with an electrophoretic run on a Bioanalyzer instrument using the RNA 6000 Nano Kit (Agilent). 
RNA Integrity Number was determined for every sample and all the samples were considered suitable for pro-
cessing based on the RNA integrity (RIN > 8). RNA concentration was estimated through spectrophotometric 
measurement using a Nanoquant Infinite M200 instrument (Tecan). Sequencing libraries were prepared using the 
TruSeq™ RNA Sample Preparation Kit (Illumina) using 1.8 ug of total RNA as input. Polyadenylated transcripts 
were purified using poly-T oligo-attached magnetic beads. PolyA RNA was fragmented at 94 °C for 8 min and 
retrotranscribed using random hexamers. Multiple indexing adapters were ligated to the ends of the cDNA and 
the amount of DNA in the library was amplified with 10 PCR cycles. Final libraries were validated and quantified 
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with the DNA1000 kit on the Agilent Bioanalyzer Instrument. Pooled libraries were sequenced on the Illumina 
Genome Analyzer IIx producing an average of 13 M reads per library.
Bioinformatics analysis. BaseCall files were converted to FastQ files using Casava 1.8.2. Sequencing reads 
were aligned to the mouse genome (mm10) using TopHat v.2.0.9. Transcripts were reconstructed and quantified 
using Cufflinks v2.1.1 and differential expression analysis was performed using CuffDiff58. CuffDiff uses the test 
statistics T = E[log(y)]/Var[log(y)], where y is the ratio of the normalized counts between two conditions. A t-test 
is used to calculate the P value for Differential Expression59. A threshold of 0.05 was applied to False Discovery 
Rate (FDR) adjusted p values in order to select the differentially expressed genes (DEGs) to use in downstream 
analysis; we also included genes with a log2 fold-change (lgFC) > 1 either showing one anomalous triplicate 
FPKM value and an FPKM average value between 1 and 2. Heat map of DEGs was made with Genesis software 
using triplicates mean, after normalization and log2 transformation. Cluster analysis was performed with the 
Genesis software tool using k-means clustering function (k = 8) in order to identify group of genes with a sim-
ilar regulation at 3 and 24 h of treatment60; genes with lgFC > + /− 0.40 were selected. In each cluster of genes, 
the regulatory sequences in 20 Kb around the transcription start site were analyzed using iRegulon Cytoscape 
App and candidate transcription factors were predicted61. Overrepresentation analysis (ORA) on DEGs lists was 
performed using the Functional Annotation Tool in DAVID website62. The lists of DEGs at 3 and 24 h of estra-
diol treatment were used as input gene list and the mouse genome was used as background list. Biological pro-
cesses, molecular functions and KEGG pathways were investigated focusing on enriched terms with a Benjamini 
adjusted p-value less than 0.05. A Protein-Protein Interaction Network of the differentially expressed genes has 
been created using STRING63.
Flow cytometry analysis. To assess cell proliferation index, CD11b-positive cells obtained from each ani-
mal were divided in 3 aliquots; 2 aliquots of 2.5 × 105 cells each were used to detect BrdU and Ki67 by flow 
cytometry, the remaining aliquot was used for gene expression. Cells were suspended in 2 ml of pre-chilled ACK 
solution. For Ki67 staining, cells were fixed in 4% paraformaldehyde for 15 min, extensively washed with 125 mM 
glycine in PBS and permeabilized o/n in PBS containing 0,5% Triton X-100 and 1% BSA, at 4 °C. Cells were 
incubated with rabbit anti-mouse Ki67 antibody conjugated with eFluor660 (eBioscence-Affymetrix) diluted 
1:100 in Incubation Solution (PBS containing 0.5% Triton X-100 and 0.05% BSA) at room temperature for 1 h. 
After extensive washes in PBS, cells were analyzed with a flow cytometry system (BD FACS Calibur). For BrdU 
staining, cells were fixed and permeabilized in 70% EtOH for 30 min at 4 °C and DNA was denaturated with 
2 N HCl/0.5% Triton X-100 and incubated 30 min at room temperature. Cells were washed with 0.1 M sodium 
tetraborate (pH 8.5) and incubated with rat anti-mouse BrdU antibody (AbD Serotec) diluted 1:100 in Incubation 
Solution (PBS containing 0.05% Tween-20 and 1% BSA). After washes in PBS/1%BSA, cells were incubated with 
Alexa488-conjugated goat anti-rat secondary antibody (1:200 in incubation solution; Molecular Probes) for 1 h 
at room temperature. Cells were extensively washed with PBS, resuspended in PI solution (H2O containing 10% 
NP40, 1 mg/ml RNase A and 5 μ g/ml PI stock; Sigma-Aldrich). Samples were analyzed using FACSCalibur and 
analyzed with FlowJo version 9 software (Tree Star). Animals with no pulse of BrdU were used for gating strategy 
to evaluate nonspecific signals.
In the sham/ovx animals and in the zymosan-induced peritonitis model, immunofluorescent staining of peri-
toneal cells was performed with V450 anti-mouse CD45, PerCP-Cy5.5 anti- mouse CD11b, FITC anti-mouse 
Ly6C, PE-Cy7 anti-mouse Ly6G, PE anti-mouse CD11c, PE anti-mouse CD19 (BD Biosciences), AlexaFluor 647 
anti-mouse F4/80 (AbD Serotec) and PE anti-mouse CCR3 (R&D Systems). Samples were analyzed using FACS 
Canto II and DIVA software (BD Biosciences); gating strategies are reported in Supplementary Fig. 1. Resolution 
indices of zymosan-induced peritonitis were calculated as previously described57. Ly6G-negative CD11b-positive 
and F4/80-positive macrophages were sorted using sorter Aria (FACS Aria, Becton Dickinson Biosciences) and 
resuspended in TRIzol reagent for gene expression analyses.
Data availability. Data is available at the NCBI repository through the link http://www.ncbi.nlm.nih.gov/
bioproject/376257.
Statistical analysis. Statistical significance was carried out with the GraphPad Prism version 5.02 for 
Windows by a Bonferroni post hoc test for multiple comparisons. Unless otherwise stated, “n” indicates biological 
replicates.
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